Charles River Laboratories International (CRL) 10-Q2024 Q1 Quarterly report

Filed: 9 May 24, 9:17am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: accreted, adequate, alleging, approach, asserting, biomedical, breached, Carlo, categorized, Chair, clarify, CODM, conform, cumulative, Decision, Delaware, depending, disaggregation, disproportionate, dividend, domestic, endedMarch, endotoxin, environmental, Exact, extent, fail, failing, fiduciary, healthier, Krona, Maker, Mauritian, method, milestone, mission, Monte, Noveprim, offering, Parisotto, participant, payable, plant, property, purpose, reconciliation, reduced, regularly, retrospective, Rupee, separately, Shannon, Simulation, standard, stay, step, stockholder, Swedish, Topic, toxicological, unfavorable, upcoming, vertically

Removed: adverse, agreement, amendment, assessed, Avian, backlog, banking, begun, biopharmaceutical, borrowed, broader, chicken, conflict, continuation, cord, country, criteria, customary, cybersecurity, deployed, designated, discounted, diversified, divesting, divestiture, earn, efficiently, enabled, enact, European, evaluate, evolve, executed, expedient, Explora, Federation, fit, footprint, Forint, forward, full, fundamental, funding, gene, hedging, hold, Hungarian, impacted, indirect, inflation, inflationary, invasion, investor, launched, LIBOR, limit, loan, mitigate, modification, modified, modifying, moving, optional, private, promising, qualitative, quantitative, Reform, regime, region, remained, repaying, replacing, reset, routinely, Russia, Russian, secure, selected, settlement, situation, sparked, specifically, stability, subsequent, Subtopic, supplied, therapy, tied, turnkey, Ukraine, Union, Vaccine, variety, voting, widespread

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated CRL transcripts

CRL similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report on Form 10-Q for the quarter ended March 30, 2024 of Charles River Laboratories International, Inc. (the “Company”) as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, James C. Foster, Chairman, President and Chief Executive Officer of the Company, and Flavia H. Pease, Corporate Executive Vice President and Chief Financial Officer of the Company, each hereby certifies, to the best of his knowledge and pursuant to 18 U.S.C. Section 1350, that:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (the “Exchange Act”); and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ James C. Foster

May 9, 2024

James C. Foster

Chairman, President and Chief Executive Officer

Charles River Laboratories International, Inc.

/s/ Flavia H. Pease

May 9, 2024

Flavia H. Pease

Corporate Executive Vice President and Chief Financial Officer

Charles River Laboratories International, Inc.

This certification shall not be deemed "filed" for any purpose, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Exchange Act.